Sorafenib in sequential therapy of metastatic renal cell carcinoma
Prognosis of the disease and survival of patients has significantly improved after researchers identified the pathology of metastatic renal cell carcinoma (MRCC) and developed target treatments. New clinical studies and search for innovative drugs and treatment schemes are encouraged by drug resistance and intolerance caused by long-term pharmacotherapy. The article tells about the results of efficiency and tolerability studies of sorafenib in the first- and second-line treatment of MRCC.